P3371

Penfluridol

≥97% (HPLC), powder

• Sinónimos: 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3(trifluoromethyl)phenyl]-4-piperidinol, R16341
• Fórmula empírica (notación de Hill): C₂₈H₂₇ClF₅NO
• Número CAS: 26864-56-2
• Peso molecular: 523.97
• NACRES: NA.77
• PubChem Substance ID: 329820171
• UNSPSC Code: 12352200
• EC Number: 248-074-5
• MDL number: MFCD00866714
• Assay: ≥97% (HPLC)
• Form: powder

Propiedades

• assay: ≥97% (HPLC)
• form: powder
• color: white
• solubility: DMSO: >20 mg/mL, H₂O: insoluble
• originator: Johnson & Johnson
• storage temp.: 2-8°C
• SMILES string: OC1(CCN(CCCC(c2ccc(F)cc2)c3ccc(F)cc3)CC1)c4ccc(Cl)c(c4)C(F)(F)F
• InChI: 1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
• InChI key: MDLAAYDRRZXJIF-UHFFFAOYSA-N

Descripción

Application

Penfluridol has been used as an antipsychotic agent:

• to study its antimetastatic effect on triple-negative breast cancer cells[1]
• to study its effects on the growth of glioblastoma cell lines[1],
• to study its effects on the vascular endothelial growth factor (VEGF)-induced angiogenesis in human umbilical vein endothelial cells (HUVECs)[2]

Biochem/physiol Actions

Penfluridol is studied in the treatment of schizophrenia, Tourette syndrome and acute psychosis.[2] It also exhibits anticancer activity.[1]

T-type Ca²⁺ channel blocker; antipsychotic

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS06
• signalword: Danger
• hcodes: H301
• pcodes: P264 - P270 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Oral
• Clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• ppe: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges